NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/04/2026 16:00
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization375.55 mln
Float262 mln
Earnings Date05/07/2026
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.88
Likely reliable
Relative Strength
85
/ 100
Strongly outperforming
Debt / Equity
1.59
High leverage
Pre-Tax Margin
9.95%
Moderate margin
ROE
-33.91
Deeply negative
Business Description
Akebia Therapeutics is a Massachusetts-based medical company founded in 2007 that develops and sells treatments for people living with kidney disease. Its two approved medicines help patients manage anemia and high phosphorus levels associated with chronic kidney disease, while two additional drugs are currently being tested in clinical trials for conditions including kidney injury following heart surgery and an eye disorder affecting premature newborns. The company markets its products across multiple regions through licensing partnerships with pharmaceutical firms in Japan, Asia, and other territories.
